These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24438630)

  • 1. Vitamin D receptor and its protective role in diabetic nephropathy.
    Guan X; Yang H; Zhang W; Wang H; Liao L
    Chin Med J (Engl); 2014; 127(2):365-9. PubMed ID: 24438630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective role of the vitamin D receptor.
    Yang L; Ma J; Zhang X; Fan Y; Wang L
    Cell Immunol; 2012 Oct; 279(2):160-6. PubMed ID: 23246677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism.
    Hu X; Liu W; Yan Y; Liu H; Huang Q; Xiao Y; Gong Z; Du J
    Eur J Pharmacol; 2019 Feb; 845():91-98. PubMed ID: 30287151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.
    Pérez-Gómez MV; Ortiz-Arduán A; Lorenzo-Sellares V
    Nefrologia; 2013; 33(5):716-26. PubMed ID: 24089164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
    Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
    Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotection with vitamin D: specific for diabetic nephropathy?
    Klaus G
    Kidney Int; 2008 Jan; 73(2):141-3. PubMed ID: 18165810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition.
    Eltablawy N; Ashour H; Rashed LA; Hamza WM
    Arch Physiol Biochem; 2018 Dec; 124(5):461-467. PubMed ID: 29308676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of vitamin D3 in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Zhao J; Dong J; Wang H; Shang H; Zhang D; Liao L
    Chin Med J (Engl); 2014; 127(15):2837-43. PubMed ID: 25146624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
    Agarwal R
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1523-8. PubMed ID: 19478099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Role of Vitamin D and Vitamin D Receptor in Diabetic Nephropathy.
    Lei M; Liu Z; Guo J
    Biomed Res Int; 2020; 2020():4137268. PubMed ID: 32766307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D and Diabetic Kidney Disease.
    Huang HY; Lin TW; Hong ZX; Lim LM
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Vitamin D in Diabetic Nephropathy: A Translational Approach.
    Delrue C; Speeckaert R; Delanghe JR; Speeckaert MM
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of a local renin angiotensin system in podocytes by glucose.
    Durvasula RV; Shankland SJ
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F830-9. PubMed ID: 18216149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
    Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
    Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.